XOMA Stock Analysis: Buy, Sell, or Hold?
XOMA - XOMA Royalty Corporation Common Stock
$40.86
-1.11 (-2.64%)
▼
5d:
+3.23%
30d:
+35.43%
90d:
+58.93%
HOLD
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 12, 2026
12d
Get Alerted When XOMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XOMA trades at premium valuation expecting 10.9% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: XOMA trades at premium valuation expecting 10.9% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.26
Based on -16.9% avg growth
INTRINSIC VALUE TODAY
$3.88
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XOMA is currently trading at $40.86, which is considered extended relative to its 30-day fair value range of $30.77 to $39.29. From a valuation perspective, the stock is trading at a premium (Forward PE: 59.6) compared to its historical average (43.8). At these levels, the market is pricing in 10.9% annual earnings growth.
Technical Outlook: Technically, XOMA is in a uptrend. Immediate support is located at $37.00, while resistance sits at $42.81.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $59.00 (+44.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XOMA is in a uptrend. Immediate support is located at $37.00, while resistance sits at $42.81.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $59.00 (+44.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$30.77 -
$39.29
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.3%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.4% below Wall St target ($59.00)
- BULLISH: Expecting earnings turnaround to 10.9% growth with 57.9% revenue growth
Trading Range Analysis
30-Day Trading Range
$30.77 -
$39.29
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$37.00
Resistance Level
$42.81
Current Trend
Uptrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
59.65
Wall Street Target
$59.00
(+44.4%)
Revenue Growth (YoY)
57.9%
Earnings Growth (YoY)
-47.8%
Profit Margin
60.8%
Valuation Premium vs History
+10.9% premium
PE vs Historical
59.7 vs 43.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.9%
(market-implied from PE analysis)
1-Year Target
$45.31
(+11%)
2-Year Target
$50.25
(+23%)
3-Year Target
$55.73
(+36%)
3-Yr Target (if PE normalizes)
(PE: 60→44)
PE COMPRESSION
$40.92
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 59.6, Growth: -37.8%)
$29.79
(+-27%)
Base:
(SPY PE: 20.6, Growth: -37.8%)
$10.29
(-75%)
Bear:
(PE: 17.5, Growth: -37.8%)
$8.75
(-79%)
📈
Valuation based on Current Earnings
Trailing PE: 28.75 | Current EPS (TTM): $1.46
Bull Case
$23.08
(-44%)
Analyst growth -50.0%, PE expands to 31.6
Base Case
$20.99
(-49%)
Market implied -50.0%, PE stable at 28.8
Bear Case
$28.54
(-30%)
Severe decline -20.0%, PE contracts to 24.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 29, 2026 6:12 AM ET
Data refreshes hourly during market hours. Next update: 7:12 AM
Data refreshes hourly during market hours. Next update: 7:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XOMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Owen Hughes
BUY
100000 shares
2025-12-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 59 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$878 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
